132 related articles for article (PubMed ID: 2652582)
1. Treatment of acute cellular kidney allograft rejection with T10B9.1A-31A anti T-cell monoclonal antibody.
Waid TH; Lucas BA; Thompson JS; Brown S; Moore D; Amlot P; Janossy G
Transplant Proc; 1989 Feb; 21(1 Pt 2):1778-84. PubMed ID: 2652582
[No Abstract] [Full Text] [Related]
2. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
[TBL] [Abstract][Full Text] [Related]
3. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients.
Waid TH; Lucas BA; Thompson JS; Brown SA; Munch L; Prebeck RJ; Jezek D
Transplantation; 1992 Jan; 53(1):80-6. PubMed ID: 1531095
[TBL] [Abstract][Full Text] [Related]
4. Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.
Alausa M; Almagro U; Siddiqi N; Zuiderweg R; Medipalli R; Hariharan S
Clin Transplant; 2005 Feb; 19(1):137-40. PubMed ID: 15659147
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD4 monoclonal antibody therapy of late acute rejection in renal allograft recipients--CD4+ T cells play an essential role in the rejection process.
Reinke P; Kern F; Fietze E; Döcke WD; Ewert R; Emmrich F; Volk HD
Transplant Proc; 1995 Feb; 27(1):859-62. PubMed ID: 7879207
[No Abstract] [Full Text] [Related]
6. Monoclonal antibodies to human T cell subsets: use for immunological monitoring and immunosuppression in renal transplantation.
Burton RC; Cosimi AB; Colvin RB; Rubin RH; Delmonico FL; Goldstein G; Russell PS
J Clin Immunol; 1982 Jul; 2(3 Suppl):142S-147S. PubMed ID: 6290526
[TBL] [Abstract][Full Text] [Related]
7. Definition, diagnosis, and treatment of acute kidney rejection--the first 30 days.
Howard RJ
Transplant Proc; 1986 Apr; 18(2 Suppl 1):92-103. PubMed ID: 2421468
[No Abstract] [Full Text] [Related]
8. Acute interstitial nephritis of plasma cells: a new cause for renal allograft loss.
David-Neto E; Ribeiro DS; Ianhez LE; Palomino S; Saldanha LB; Arap S; Sabbaga E
Transplant Proc; 1993 Feb; 25(1 Pt 2):897-9. PubMed ID: 8442259
[No Abstract] [Full Text] [Related]
9. Anti-T12 monoclonal antibody therapy of acute renal allograft rejection.
Milford EL; Carpenter CB; Kirkman RL; Tilney NL; Mazoujian G; Strom TB; Lazarus JM; Schlossman SF; Guttmann RD; Lowry R
Transplant Proc; 1987 Feb; 19(1 Pt 3):1910. PubMed ID: 3274450
[No Abstract] [Full Text] [Related]
10. Monoclonal antibody identification of nucleated cells in urine: diagnosis of allograft rejection.
Segasothy M; Birch DF; Fairley KF; Kincaid-Smith P
Transplant Proc; 1989 Feb; 21(1 Pt 2):1878-9. PubMed ID: 2652610
[No Abstract] [Full Text] [Related]
11. Anti-LFA-1 adhesion molecule monoclonal antibody in prophylaxis of human kidney allograft rejection.
Le Mauff B; Hourmant M; Le Meur Y; Dantal J; Cantarovich D; Caudrelier P; Alberici G; Soulillou JP
Transplant Proc; 1995 Feb; 27(1):865-6. PubMed ID: 7879210
[No Abstract] [Full Text] [Related]
12. Immunoexpression of perforin and granzyme B on infiltrating lymphocytes in human renal acute allograft rejection.
Wagrowska-Danilewicz M; Danilewicz M
Nefrologia; 2003; 23(6):538-44. PubMed ID: 15002789
[TBL] [Abstract][Full Text] [Related]
13. OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatments.
Goldstein G; Norman DJ; Shield CF; Kreis H; Burdick J; Flye MW; Rivolta E; Starzl T; Monaco A
Prog Clin Biol Res; 1986; 224():239-49. PubMed ID: 3540993
[No Abstract] [Full Text] [Related]
14. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
[No Abstract] [Full Text] [Related]
15. Acute kidney graft rejection. A morphological and immunohistological study on "zero-hour" and follow-up biopsies with special emphasis on cellular infiltrates and adhesion molecules.
Andersen CB; Ladefoged SD; Larsen S
APMIS; 1994 Jan; 102(1):23-37. PubMed ID: 7513171
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute kidney rejection episodes with monoclonal antibody directed against IL2 receptor: a pilot study.
Cantarovich D; Le Mauff B; Hourmant M; Giral M; Denis M; Hirn M; Jacques Y; Soulillou JP
Transplant Proc; 1989 Feb; 21(1 Pt 2):1785-6. PubMed ID: 2652583
[No Abstract] [Full Text] [Related]
17. Detection of B lymphocytes (CD20+) in renal allograft biopsy specimens.
Martins HL; Silva C; Martini D; Noronha IL
Transplant Proc; 2007 Mar; 39(2):432-4. PubMed ID: 17362749
[TBL] [Abstract][Full Text] [Related]
18. The effects of OKT3 anti-rejection therapy on in situ allograft infiltrating lymphocytes.
Kerr PG; Atkins RC
Transplant Proc; 1989 Feb; 21(1 Pt 1):977-8. PubMed ID: 2650302
[No Abstract] [Full Text] [Related]
19. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.
Monaco A; Goldstein G; Barnes L
Transplant Proc; 1987 Apr; 19(2 Suppl 1):28-31. PubMed ID: 3105137
[No Abstract] [Full Text] [Related]
20. Monoclonal anti-T12 antibody as therapy for renal allograft rejection.
Carpenter CB; Milford EL; Reinherz EL; Schlossman SF; Tilney NL; Strom TB; Kirkman RL; Busch GJ; Araujo JL
Trans Assoc Am Physicians; 1983; 96():84-92. PubMed ID: 6388105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
